Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).
KPC Pharmaceuticals, Inc., partially owned by China Resources Pharmaceutical Group Ltd., reported a decrease in revenue and net profit for the nine months ending September 30, 2025, compared to the previous year. The financial results indicate a net decrease in cash and cash equivalents, highlighting potential challenges in liquidity. The announcement advises caution for shareholders and potential investors due to the unaudited nature of the financials, which may require adjustments.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a significant player in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company holds a substantial equity interest in KPC Pharmaceuticals, Inc., a firm listed on the Shanghai Stock Exchange, through its subsidiary China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Average Trading Volume: 16,744,630
Technical Sentiment Signal: Sell
Current Market Cap: HK$30.6B
Learn more about 3320 stock on TipRanks’ Stock Analysis page.